Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T01:51:04.910Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of milrinone on hemodynamic and gas exchange parameters in children

Published online by Cambridge University Press:  17 December 2019

Rohit S. Loomba Open the ORCID record for Rohit S. Loomba [Opens in a new window] ,
Vincent Dorsey ,
Enrique G. Villarreal Open the ORCID record for Enrique G. Villarreal [Opens in a new window]  and
Saul Flores
Rohit S. Loomba
Affiliation:
Cardiology, Pediatrics, Advocate Children’s Heart Institute, Advocate Children’s Hospital, Oak Lawn, IL, USA Medicine, Chicago Medical School/Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
Vincent Dorsey
Affiliation:
Cardiology, Pediatrics, Advocate Children’s Heart Institute, Advocate Children’s Hospital, Oak Lawn, IL, USA
Enrique G. Villarreal*
Affiliation:
Critical Care and Cardiology, Pediatrics, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX, USA Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico
Saul Flores
Affiliation:
Critical Care and Cardiology, Pediatrics, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX, USA
*
Author for correspondence: E. G. Villarreal, MD, Cardiac Intensive Care Unit, Section of Critical Care and Cardiology, Texas Children’s Hospital, Research Scholar Baylor College of Medicine, Houston, TX, USA. Tel: +1 312 282 6935; Fax: +1 832 825 2969; E-mails: [email protected]; [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Milrinone is a drug frequently used for hemodynamic support in children during critical illness. Although the hemodynamic changes induced by milrinone in children may appear similar to those of adults, the physiologic contributors of these changes remain vastly unknown. A systematic review was conducted to identify studies characterising the hemodynamic effects of milrinone in children during critical illness for hemodynamic support for various medical conditions. Studies were assessed for quality and those of satisfactory quality with pre- and post-operative hemodynamics for each patient were included in the final analyses. Those not limited to children and those not limited to patients with critical illness were excluded from the final analyses. A total of six studies with 791 patients were included in the final analyses. Milrinone infusion doses ranged from 0.3 to 0.75 mcg/kg/minute with the mean infusion dose being 0.5 mcg/kg/minute. Patients whom received milrinone infusion had greater cardiac output, greater left ventricle shortening fraction, lower right ventricular systolic pressure, and lower serum lactate levels. Systolic blood pressure mean arterial blood pressure and arterial oxygen concentration did not significantly change with administration of milrinone. These results were irrespective of milrinone infusion dose, infusion duration, and study size. Milrinone was found to have several beneficial hemodynamic effects in children during critical illness when used at usual clinical doses.

Keywords

Paediatricsmilrinoneintensive care unitsphosphodiesterase 3 inhibitorsheart disease
Type
Original Article
Information
Cardiology in the Young , Volume 30 , Issue 1 , January 2020 , pp. 55 - 61
Copyright
© Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Maskin, CS, Sinoway, L, Chadwick, B, Sonnenblick, EH, Le Jemtel, TH.Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 1983; 67: 1065–1070.CrossRefGoogle ScholarPubMed
Alousi, AA, Canter, JM, Montenaro, MJ, Fort, DJ, Ferrari, RA.Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 792–803.CrossRefGoogle ScholarPubMed
Silver, PJ, Harris, AL, Canniff, PC, et al.Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J Cardiovasc Pharmacol 1989; 13: 530–540.CrossRefGoogle ScholarPubMed
LeJemtel, TH, Scortichini, D, Levitt, B, Sonnenblick, EH.Effects of phosphodiesterase inhibition on skeletal muscle vasculature. Am J Cardiol 1989; 63: 27a–30a.CrossRefGoogle ScholarPubMed
Sinoway, LS, Maskin, CS, Chadwick, B, Forman, R, Sonnenblick, EH, Le Jemtel, TH.Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983; 2: 327–331.CrossRefGoogle ScholarPubMed
Baim, DS, McDowell, AV, Cherniles, J, et al.Evaluation of a new bipyridine inotropic agent – milrinone – in patients with severe congestive heart failure. N Engl J Med 1983; 309: 748–756.CrossRefGoogle ScholarPubMed
Hoffman, TM, Wernovsky, G, Atz, AM, et al.Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics. Am Heart J 2002; 143: 15–21.CrossRefGoogle Scholar
Cavigelli-Brunner, A, Hug, MI, Dave, H, et al.Prevention of low cardiac output syndrome after pediatric cardiac surgery: a double-blind randomized clinical pilot study comparing dobutamine and milrinone. Pediatr Crit Care Med 2018; 19: 619–625.Google ScholarPubMed
Barnwal, NK, Umbarkar, SR, Sarkar, MS, Dias, RJ.Randomized comparative study of intravenous infusion of three different fixed doses of milrinone in pediatric patients with pulmonary hypertension undergoing open heart surgery. Ann Card Anaesth 2017; 20: 318–322.CrossRefGoogle ScholarPubMed
Ushio, M, Egi, M, Wakabayashi, J, et al.Impact of milrinone administration in adult cardiac surgery patients: updated meta-analysis. J Cardiothorac Vasc Anesth 2016; 30: 1454–1460.CrossRefGoogle ScholarPubMed
James, AT, Bee, C, Corcoran, JD, McNamara, PJ, Franklin, O, El-Khuffash, AF.Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series. J Perinatol 2015; 35: 268–273.CrossRefGoogle ScholarPubMed
James, AT, Corcoran, JD, McNamara, PJ, Franklin, O, El-Khuffash, AF.The effect of milrinone on right and left ventricular function when used as a rescue therapy for term infants with pulmonary hypertension. Cardiol Young 2016; 26: 90–99.CrossRefGoogle ScholarPubMed
McNamara, PJ, Shivananda, SP, Sahni, M, Freeman, D, Taddio, A.Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med 2013; 14: 74–84.CrossRefGoogle ScholarPubMed
Kumar, VHS, Dadiz, R, Koumoundouros, J, Guilford, S, Lakshminrusimha, S.Response to pulmonary vasodilators in infants with congenital diaphragmatic hernia. Pediatr Surg Int 2018; 34: 735–742.CrossRefGoogle ScholarPubMed
Lee, J, Kim, GB, Kwon, HW, et al.Safety and efficacy of the off-label use of milrinone in pediatric patients with heart diseases. Korean Circ J 2014; 44: 320–327.CrossRefGoogle ScholarPubMed
Bianchi, MO, Cheung, PY, Phillipos, E, Aranha-Netto, A, Joynt, C.The effect of milrinone on splanchnic and cerebral perfusion in infants with congenital heart disease prior to surgery: an observational study. Shock 2015; 44: 115–120.CrossRefGoogle Scholar
Supplementary material: File

Loomba et al. supplementary material

Loomba et al. supplementary material

Download Loomba et al. supplementary material(File)
File 17.2 KB